ReviewChronic diseases and translational medicine2017
Quantitative magnetic resonance imaging biomarkers in oncological clinical trials: Current techniques and standardization challenges.
Review in Chronic diseases and translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Multi-center diffusion-weighted MRI validation for 0.35T MR-Linac.Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB) · 2026Article
- Quantitative evaluation of apparent diffusion coefficient in a large multi-unit institution.Physics and imaging in radiation oncology · 2025Article
- Magnetic Resonance Imaging Biomarkers of Muscle.Tomography (Ann Arbor, Mich.) · 2024Review
- The role of clinical imaging in oncology drug development: progress and new challenges.The British journal of radiology · 2023Review
- Magnetic resonance biomarkers in radiation oncology: The report of AAPM Task Group 294.Medical physics · 2021Article
- Rapid multicontrast brain imaging on a 0.35T MR-linac.Medical physics · 2020Article
- SLIC-supervoxels-based response evaluation of osteosarcoma treated with neoadjuvant chemotherapy using multi-parametric MR imaging.European radiology · 2020Article
- How reliable are ADC measurements? A phantom and clinical study of cervical lymph nodes.European radiology · 2018Article
- A fast protocol for multicenter and multiparametric quantitative MRI studies in brain tumor patients using vendor sequences.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiological imaging plays an important role in oncological trials to provide imaging biomarkers for disease staging, stratifying patients, defining dose setting, and evaluating the safety and efficacy of new candidate drugs and innovative treatment. This paper reviews the techniques of most commonly used quantitative magnetic resonance imaging (qMRI) biomarkers (dynamic contrast enhanced, dynamic susceptibility contrast, and diffusion weighted imaging) and their applications in oncological trials. Challenges of incorporating qMRI biomarkers in oncological trials are discussed including understanding biological mechanisms revealed by MRI biomarkers, consideration of rigorous trial design and standardized implementation of qMRI protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.